Prime Medicine, Inc. · NASDAQ:PRME

Prime Medicine — Investor Presentation (November 2026)

44 slides from Prime Medicine's investor presentation, Nov 10, 2026

  1. Slide 1: Delivering on the promise of Prime Editing

    1 Delivering on the promise of Prime Editing Corporate Presentation November 2026

  2. Slide 2: Forward-looking statements

    2 This presentation contains forward-looking statements of Prime Medicine, Inc. ("Prime", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements contain information about our current and future prospects and our operati

  3. Slide 3: Prime Editing: Emerging as the Predominant Gene Editing Technology

    3 Prime Editing: Emerging as the Predominant Gene Editing Technology Gene editing permanently corrects genetic alterations Prime Editing is the most versatile gene editing technology Clinical data with Prime Editors support curative potential Prime Editing does not cause double-strand breaks or byst

  4. Slide 4: Prime Medicine is Strategically Delivering on the Promise of Prime Editing

    4 Focused execution on Wilson disease and Alpha-1 Antitrypsin Deficiency Initial efforts underway to expand liver franchise Prime Medicine is Strategically Delivering on the Promise of Prime Editing DISCIPLINED CLINICAL DEVELOPMENT, MAXIMIZE PLATFORM IMPACT AND E NSURE ACCESS TO BREAKTHROUGH THERAPI

  5. Slide 5: Near-Term, Focused Execution Positions Prime Medicine

    5 Secure multiple additional strategic partnerships to accelerate our pipeline and bolster our financial resources Near-Term, Focused Execution Positions Prime Medicine to Capitalize on the Full Potential of Prime Editing Achieved and Anticipated Milestones 2026 2027 WILSON DISEASE ✓PM577a CTA and I

  6. Slide 6: Pipeline by therapeutic area and indication

    6 Therapeutic Area Indication Delivery Discovery Lead Optimization IND- enabling Phase 1/2 Pivotal / Registration LIVER Wilson Disease LNP Alpha-1 Antitrypsin Deficiency (AATD) LNP LUNG Cystic Fibrosis1 (including PASSIGE ) LNP IMMUNOLOGY & ONCOLOGY p47phox Chronic Granulomatous Disease ex vivo Plan

  7. Slide 7: Leveraging the Versatility of Prime Editing Across Diseases and Tissues

    7 We Plan to Leverage the Versatility of Prime Editing to Address a Range of Diseases Across Target Tissues REPLACEMENT Deletion / Insertion Correction p47 Chronic Granulomatous Disease (CGD) Point Mutation Correction Wilson Disease, Alpha-1 Antitrypsin Deficiency Targeted Full Gene Insertion (PASSI

  8. Slide 8: Modular Prime Editing Platform Flywheel Effect

    8 Manufacturing Processes and Assays Regulatory Frameworks Clinical Development Consolidated safety and platform clinical trials Computational Design and Screening of Core Components PE proteins, RNAs, lipids Off-Target Analysis to Advance Highest Precision Guide RNAs Non-Clinical Development In-vit

  9. Slide 9: Extensive, Foundational Intellectual Property for Prime Editing

    9 Prime Medicine Holds Extensive, Foundational Intellectual Property for Prime Editing Technologies CRISPR-Cas Enzyme Any programmable nuclease to specifically identify and cut DNA sequences Guide RNA Engineered RNAs that locate the exact editing site and provide the template for transcription Rever

  10. Slide 10: Liver

    Liver Delivering on the promise of Prime Editing

  11. Slide 11: Initial Liver Franchise: Wilson Disease and AATD

    11 PM647: AATD Prime Medicine’s Initial Liver Franchise: Aspiring to Cure Two of the Largest Genetic Liver Diseases, Enabled by Platform Modularity WD = Wilson Disease; AATD = Alpha-1 Antitrypsin Deficiency; IND = investigational new drug; CTA = clinical trial application *Prime Medicine estimate PM

  12. Slide 12: Proprietary LNP-Formulated Prime Editor Drug Product

    12 Proprietary LNP-Formulated Prime Editor is a Complex Multi-Component Drug Product Designed to Support Current and Future Liver Programs Control particle size and stability, stealth coating reduces serum interactions and increases half-life PEG Lipids Stabilize and improve LNP pharmacokinetics, fa

  13. Slide 13: Wilson Disease

    13 Wilson Disease

  14. Slide 14: Advancing Prime Editors for Wilson Disease: Disease Overview

    14 Wilson Disease Advancing Prime Editors for Wilson Disease: Disease Overview Large genetically defined disease well suited for Prime Editing ceruloplasmin Blood Bile (fecal excretion) ATP7B ATP7B Copper CTR1 ceruloplasmin Blood (urinary excretion) Bile ATP7B ATP7B Copper CTR1 X X Healthy • Common

  15. Slide 15: Wilson Disease Programs: Large Commercial Opportunity

    15 Prime Medicine’s Wilson Disease Programs Have Potential to Address Large Commercial Opportunity H1069Q R778L Other Common Mutations All Other Mutations Prime Addressable Patients Up to 7k Six most common mutations account for up to 26,000 patients in addressable markets (US, Europe, Japan) with

  16. Slide 16: Efficient correction of H1069Q and R778L mutations in humanized mouse models

    16 Efficient correction of the H1069Q and R778L mutations in fully humanized mouse models Prime Editors Efficiently and Precisely Corrected the Two Most Prevalent Disease- Causing Mutations in Wilson Disease No detectable off-target editing identified in patient-derived cells for PM577a LNP = lipid

  17. Slide 17: PM577a Corrected H1069Q and Restored Wild-Type Copper Concentration

    17*ATP7B protein expression and liver copper measurements taken at 4 weeks PM577a Efficiently Corrected the H1069Q Mutation and Restored Wild-Type Copper Concentration at Multiple Doses in Preclinical Studies ~45% editing restored copper levels to near wild-type levels Liver copper restored to wild-

  18. Slide 18: Prime Edited Mice Demonstrated Normal Copper Metabolism

    18 Untreated (Wild Type) Treated (H1069Q Mut) Untreated (H1069Q Mut) Copper challenge and PET imaging performed 4 weeks post PE treatment, PET imaging performed 24hrs post copper challenge Prime Edited Mice Challenged with Radiolabeled Copper Demonstrated Normal Copper Metabolism At Multiple Doses 0

  19. Slide 19: PM577a Clinical Trial Overview

    19 Trial Overview Design Phase 1/2, open-label Population Adults and adolescents with Wilson Disease and at least one ATP7B p.H1069Q allele Treatment Single IV infusion of PM577a Primary Endpoints Safety and tolerability Key Secondary Endpoints Ability to discontinue SOC, NCC-Sp, ceruloplasmin, 24-h

  20. Slide 20: Leveraging Platform Modularity for a Majority of Wilson Disease Patients

    20IND = investigational new drug; CTA = clinical trial application; LNP = lipid nanoparticle; DC = development candidate; PMDA = Japan’s Pharmaceuticals and Medical Devices Agency We Plan to Leverage Platform Modularity to Rapidly Advance Prime Editors for a Majority of Wilson Disease Patients Goal

  21. Slide 21: Alpha-1 Antitrypsin Deficiency (AATD)

    21 Alpha-1 Antitrypsin Deficiency (AATD)

  22. Slide 22: Advancing Prime Editors for AATD: Disease Overview

    22 Advancing Prime Editors for AATD: Disease Overview AATD = Alpha-1 Antitrypsin Deficiency; A1AT = alpha-1 antitrypsin *Prime Medicine estimate • AATD is an inherited genetic disorder that causes low levels of AAT protein • Low levels of AAT protein increases the risk of lung disease (emphysema) •

  23. Slide 23: AATD Program Objective: Normalize AAT Levels in PiZZ Patients

    23 • Restore SERPINA1 gene to wild type, without bystander or other unwanted edits • Increase M-AAT levels minimally above protective threshold (~11 µM), ideally into healthy human range (>20 µM) • Maintain wild-type protein under endogenous control to protect patients during acute episodes (M -AAT

  24. Slide 24: PM647 Efficiently Corrected the Mutation In Vivo

    24M-AAT = healthy A1AT protein; Z-AAT = mutant A1AT protein; IND = investigational new drug; CTA = clinical trial application *Performed by LC-MS; **Analysis at day 7 positive control = healthy human serum PM647 Efficiently Corrected the Mutation In Vivo Resulting in M-AAT Protein Restoration at Cli

  25. Slide 25: PM647 Clinical Trial Overview

    25 Trial Overview Design Phase 1/2, open-label Population Adults with PiZZ AATD: lung-only (Group A) or lung + liver / liver-only disease (Group B) Treatment One-time IV infusion of PM647a Primary Endpoints Safety, tolerability Key Secondary Endpoints Serum AAT thresholds and isoforms; pulmonary and

  26. Slide 26: Lung

    Lung Delivering on the promise of Prime Editing

  27. Slide 27: Advancing Prime Editors for Cystic Fibrosis

    27CFTR = cystic fibrosis transmembrane conductance regulator Advancing Prime Editors for Cystic Fibrosis (CF), a Disease for Which There is No Curative Therapy Prime Medicine’s efforts in Cystic Fibrosis funded through multiple grants from the Cystic Fibrosis Foundation • Progressive, genetic diseas

  28. Slide 28: Progress Developing Prime Editors for G542X Mutated Cystic Fibrosis

    28 G542X In vitro Prime Editor in Primary HBEs Phenotypic restoration of G542X mutated CFTR in differentiated ALI culture Prime Medicine has Made Significant Progress Developing Prime Editors for G542X Mutated Cystic Fibrosis CFTR -actin Patient Prime Edited C band Healthy B band Unedited Efforts t

  29. Slide 29: Parallel Prime Editing Approaches to CF: Hotspot and PASSIGE

    29CF = cystic fibrosis; attP = complimentary recognition sequence for attB; SA = splice acceptor; 3’ UTR = 3’ untranslated region; *Exons in gray introns in black Parallel Prime Editing Approaches to CF: Hotspot and PASSIGE Hotspot PASSIGE Eight hotspot Prime Editors could address the “high unmet ne

  30. Slide 30: Immunology and Oncology

    30| Immunology and Oncology

  31. Slide 31: Chronic Granulomatous Disease (CGD)

    31 Chronic Granulomatous Disease (CGD)

  32. Slide 32: Advancing Prime Editor for CGD: Disease Overview

    32 Advancing Prime Editor for CGD: Disease Overview Rare genetic disease, characterized by defective neutrophil function • Serious life-threatening disease presents in childhood; life expectancy approximately 40 years • Results in recurrent, life-threatening infections which are difficult to eradica

  33. Slide 33: PM359 clinical results and planned BLA submission

    33 Prime Medicine plans to submit a BLA following final regulatory alignment  Successful manufacturing from single mobilizations  Tolerable myeloablative conditioning at fully therapeutic exposures with expected adverse events (transitory mucositis, pancytopenia) No serious adverse events attribu

  34. Slide 34: No Detectable Off-Target Editing, Large Deletions, or Translocations

    341Analysis of edited CD34+ cells from CGD program: Targeted in vitro Analysis of 550 potential off-target sites of off-target editing. 2Data from in vivo analysis from mouse bone marrow harvested 16 weeks after engraftment was complete. 3Cas9 nuclease-edited cells, generated by transfecting HEK293T

  35. Slide 35: Ex-Vivo CAR-T

    35 Ex-Vivo CAR-T

  36. Slide 36: CAR-T: PASSIGE and Multiplex Prime Editing

    36TRAC = T-cell receptor alpha constant; Data presented at ASH, December 2022, ASGCT, May 2023 and ASH, December 2023 CAR-T: PASSIGE and Multiplex Prime Editing is the Foundation of Prime Medicine’s Collaboration with BMS Platform modularity has potential to accelerate development of additional CAR-

  37. Slide 37: Strategic License and Collaboration Agreement with Bristol Myers Squibb

    37 Strategic License and Broad Collaboration Agreement with Bristol Myers Squibb (BMS) to Develop Prime Edited ex Vivo CAR-T Products First broad, multi-target collaboration advancing Prime Editors for the treatment of complex oncology and autoimmune indications • $110 million upfront (including $55

  38. Slide 38: Multiplex Editing of CAR-T Cells

    38 Beyond Precisely Inserting a Chimeric Antigen Receptor, We Can Simultaneously and Efficiently Multiplex Edit CAR-T Cells Prime Editors can be multiplexed to introduce multiple genomic modifications in CAR-T cells Maintained efficiency with five multiplex editsHigh efficiency multiplex editing of

  39. Slide 39: Corporate

    39| Corporate

  40. Slide 40: Our Strategy to Maximize the Therapeutic Potential of Prime Editing

    40 Our Strategy to Maximize the Broad Therapeutic Potential of Prime Editing Within Our Core Outside Our Core Enabling Innovation By pairing our internal resources with strategic partners and best-in-class enabling technologies, we aim to accelerate platform development and extend the reach of Prime

  41. Slide 41: Prime Medicine is Leading the Next Generation of Gene Editing

    41CGD = Chronic granulomatous disease; AATD = Alpha-1 Antitrypsin Deficiency; IND = investigational new drug; CTA = clinical trial application Prime Medicine is Leading the Next Generation of Gene Editing Preeminent Editing Technology  Permanently corrects genetic alterations, without causing doubl

  42. Slide 42: Appendix

    42| Appendix

  43. Slide 43: Prime Editing is Designed with a Wide Range of Genome Editing Capabilities

    43BP = base pair; KB = kilobase Prime Editing is Designed with a Wide Range of Genome Editing Capabilities Flexibility to select right approach for each indication based on editing need Prime Editing Approach Small edits (e.g., all 12 bp swaps, 1-bp to 20- bp ins or del, combinations thereof) Mid-si

  44. Slide 44: PASSIGE Technology Enables Insertion of Gene Sized Sequences

    44*Not part of Prime Medicine’s current pipeline PASSIGE Technology Enables Prime Editing to Insert Gene Sized Sequences Precisely, Potentially Addressing Large Markets PASSIGE: Prime-Assisted Site-Specific Integrase Gene Editing: One step non-viral multi-kilobase-size gene editing approach with no

Prime Medicine — Investor Presentation (November 2026) on 6ix